Valuation: Gilead Sciences, Inc.

Market Cap 179B 159B 149B 135B 254B 17,233B 256B 1,787B 694B 8,795B 671B 657B 28,298B P/E 2026 *
-43.6x
P/E 2027 * 18x
Enterprise Value 196B 174B 163B 147B 278B 18,846B 280B 1,955B 759B 9,619B 734B 718B 30,948B EV / Sales 2026 *
6.37x
EV / Sales 2027 * 5.75x
Free-Float
99.88%
Yield 2026 *
2.28%
Yield 2027 * 2.32%
Oct. 06 Cognizant, Gilead Sign 5-Year Tech Extension Covering DevOps, AI Tools MT
Oct. 05 Nurix Therapeutics, Gilead Sciences Agree on Two-Year Research Term Extension for Oncology Program MT
Oct. 02 Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says MT
Sep. 28 Mirum's liver infection drug lowers virus levels in late-stage study RE
Sep. 25 HEALTH ROUNDS-Genetic discovery yields clues toward reversal of Alzheimer's brain damage RE
Sep. 23 Hackensack Meridian Center for Discovery and Innovation, Gilead Sciences and the Rockefeller University Collaborate to Research Oral Treatments for Mosquito-Borne Flaviviruses CI
Sep. 18 Dr. Reddy's Confirms License for Gilead's Yearly-Once HIV Drug; Shares Up 2% MT
Sep. 16 Gilead Sciences Insider Sold Shares Worth $432,646, According to a Recent SEC Filing MT
Sep. 16 Gilead Sciences, Inc. Expands Royalty-Free Voluntary Licensing Agreements For Lenacapavir With Dr. Reddy?s Laboratories Limited, Emcure Pharmaceuticals Limited, Eva Pharma For Pharmaceutical Industries S.A.E., Ferozsons Laboratories Limited, Hetero And Mylan Laboratories Limited CI
Sep. 16 Gilead Sciences Expands Licensing Agreements for HIV Treatment MT
Sep. 15 Gilead Sciences, Inc. and Pan American Health Organization Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean CI
Sep. 15 Gilead Sciences, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 10:45 AM
Sep. 15 Gilead Sciences Expands Lenacapavir Access to 14 Countries MT
1 day-0.28%
1 week-5.24%
Current month-3.23%
1 month-4.48%
3 months+9.87%
6 months+3.24%
Current year+17.51%
1 week 142.6
Extreme 142.5982
151.28
1 month 142.6
Extreme 142.5982
154.2
Current year 116.88
Extreme 116.88
157.29
1 year 112.82
Extreme 112.82
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/26 Sell

Chief Executive Officer

-15,000 0.0012%
9/22/26 Exercice

Controller/Auditor

5,214 0.0004%
9/15/26 Sell

Executive/Senior Manager

-3,000 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-0.28%-5.24%+27.99%+93.08% 179B
+1.26%-2.30%+37.82%+113.76% 1,019B
+0.73%-6.31%+35.06%+62.14% 610B
+0.35%+0.15%+14.01%+80.87% 470B
+1.72%-4.54%+59.14%+37.01% 344B
+0.26%-1.58%+21.97%+41.79% 336B
+0.60%-3.48%+11.37%+34.33% 266B
+1.65%-4.27%-5.47%+9.69% 241B
-0.09%-3.71%+35.15%+51.88% 218B
-0.51%-2.66%-35.19%-61.38% 164B
Average +0.28%-3.48%+20.19%+46.32% 384.66B
Weighted average by Cap. +0.27%-3.45%+26.74%+64.46%

Financials

2026 *2027 *
Net sales 30.7B 27.28B 25.55B 23.14B 43.63B 2,958B 43.98B 307B 119B 1,510B 115B 113B 4,858B 32.68B 29.04B 27.2B 24.63B 46.44B 3,149B 46.82B 327B 127B 1,607B 123B 120B 5,171B
Net income -4.27B -3.8B -3.56B -3.22B -6.07B -412B -6.12B -42.72B -16.58B -210B -16.05B -15.7B -676B 10.28B 9.13B 8.55B 7.74B 14.6B 990B 14.72B 103B 39.85B 505B 38.57B 37.74B 1,626B
Net Debt 16.75B 14.88B 13.93B 12.62B 23.8B 1,614B 23.99B 167B 64.95B 824B 62.85B 61.5B 2,650B 9.12B 8.11B 7.59B 6.88B 12.97B 879B 13.07B 91.19B 35.39B 449B 34.25B 33.51B 1,444B
Projected Income Statement - Annual - Gilead Sciences, Inc.
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-10-06 $144.23 -0.28% 3,722,746
26-10-05 $144.63 -0.08% 6,138,328
26-10-02 $144.74 -1.87% 5,044,221
26-10-01 $147.50 -1.04% 4,438,698
26-09-30 $149.05 -1.47% 5,357,405
Trader
Investor
Global
Quality
ESG MSCI
AA
Ratings Surperformance© - Gilead Sciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
144.23USD
Average target price
158.65USD
Spread / Average Target
+10.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Gilead Sciences, Inc.
  1. Stock Market
  2. Stocks
  3. GILD Stock